Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 8/20 | 0.39 |
| ▸ | FPR1 | P21462 | 5/20 | 0.39 |
| ▸ | CCNC | P24863 | 2/20 | 0.36 |
| ▸ | CDK8 | P49336 | 2/20 | 0.36 |
| ▸ | CXCR3 | P49682 | 3/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | CCR3 | P51677 | 3/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.31 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26090446 | 1.00 | FPR2 (0.39) | FPR2FPR1CCNCCDK8CXCR3 | |
| SCHEMBL26087705 | 0.92 | FPR1 (0.43) | FPR2FPR1CCNCCDK8CXCR3 | |
| SCHEMBL26435813 | 0.92 | FPR1 (0.43) | FPR2FPR1CCNCCDK8CXCR3 | |
| SCHEMBL30407271 | 0.92 | FPR1 (0.43) | FPR2FPR1CCNCCDK8CXCR3 | |
| SCHEMBL30408943 | 0.90 | EPHX2 (0.42) | FPR2FPR1CCNCCDK8CXCR3 | |
| SCHEMBL26435433 | 0.90 | EPHX2 (0.42) | FPR2FPR1CCNCCDK8CXCR3 | |
| SCHEMBL26087474 | 0.90 | EPHX2 (0.42) | FPR2FPR1CCNCCDK8CXCR3 | |
| SCHEMBL26436130 | 0.89 | EPHX2 (0.39) | CCNCCDK8CXCR3TRPV1EPHX2 | |
| SCHEMBL26089308 | 0.89 | EPHX2 (0.39) | CCNCCDK8CXCR3TRPV1EPHX2 | |
| SCHEMBL26436052 | 0.87 | POLB (0.33) | FPR2FPR1POLBCCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240308976-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND USES THEREOF | MONTE ROSA THERAPEUTICS AG (CH) | 2024-09-19 | — | — | US | disclosed |
| WO-2023069708-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND USES THEREOF | MONTE ROSA THERAPEUTICS, INC. (US) | 2023-04-27 | — | — | WO | disclosed |
| WO-2023069708-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND USES THEREOF | MONTE ROSA THERAPEUTICS, INC. (US) | 2023-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240308976-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND USES THEREOF | CRBN, GSPT1, GSPT2 | FPR2 2919/4885FPR1 1564/4885CCNC 4000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.